

ACCENT PHARMA, JAMMU
QUALITY CONTROL DEPARTMENT
Finished Product Certificate of Analysis
(Under Drugs & Cosmetics Act 1940 & rules made there under)

PRODUCT: Minisprin 75	
GENERIC NAME : ASPIRIN GASTRO – RESISTANT TABLETS IP 75MG	
A.R. No.: AP/02/FP/26/169	Batch Size: 30.0 Lac.
Batch No.: AMR26002	Date of Sampling: 14/03/2026
Mfg. Date: MAR. 2026	Quantity Sampled: 154 Tablets
Exp. Date: FEB. 2028	Date of Analysis: 16/03/2026
Manufactured for: American Remedies	Date of Release : 07/04/2026
STP No.: AP/02/FP/M002/00	

Sr. No.	Test	Limit	Observation
1.	Description	White coloured, circular shaped, slightly biconvex, plain surface gastro resistant tablet.	White coloured, circular shaped, slightly biconvex, plain surface gastro resistant tablet.
2.	Identification	A(By HPLC) Retention time of the major peak of sample preparation corresponds to that of standard as obtained in the assay. B(BY IR) The infra red spectrum of a KBr dispersion of it, previously dried exhibits maxima only at the same wavelengths as that of similar preparation of working standard.	Complies
3.	Average Weight of tablet	112.00mg ± 5% (106.4mg - 117.6 mg)	110.20mg
4.	Uniformity of weight	Average weight ± 7.5%	+2.62% -2.58%
5.	Thickness of tablets	3.2 ± 0.2mm (3.0mm-3.4 mm)	Min.3.08mm. Max.3.15mm.
6.	Diameter of tablets	6.0 ± 0.2mm (5.8mm-6.2mm)	Min.6.03mm. Max.6.15mm.
7.	Hardness of tablets	NLT 30 Newton (N)	Min.52.71N Max.58.47N
8.	Disintegration Test	In Acid (0.1M HCl): No tablet show any evidence of disintegration, cracking or softening (apart from fragments of coating) or cracks for 2 hour at 37° C ±2° C	complies
		In Buffer (Phosphate buffer PH 6.8): Not more than 60 minutes at 37° C ±2° C	12 min.15 Sec.
9.	Dissolution: (By UV) For Aspirin a) In 0.1M HCl acid for 2 hours	Not more than 10.0%	Avg.1.69% Max.2.06% Min.1.13%
	b) In mix phosphate buffer pH 6.8 for 45 minutes.	Not less than 70.0% (Q)	Avg.97.29% Max.99.96% Min.95.58%
10.	Salicylic acid (By HPLC)	Not more than 3.0%	0.13%

APPROVED

Prepared By		Checked By	Approved By
Name	Kamarkhan	Aswani Kumar	Raj Kiran
Sign.			
Date	07/04/2026	07/04/2026	07/04/2026

ACCENT PHARMA, JAMMU
QUALITY CONTROL DEPARTMENT
Finished Product Certificate of Analysis
(Under Drugs & Cosmetics Act 1940 & rules made there under)

PRODUCT: Minisprin 75	
GENERIC NAME : ASPIRIN GASTRO - RESISTANT TABLETS IP 75MG	
A.R. No.: AP/02/FP/26/169	Batch Size: 30.0 Lac.
Batch No.: AMR26002	Date of Sampling: 14/03/2026
Mfg. Date: MAR. 2026	Quantity Sampled: 154 Tablets
Exp. Date: FEB. 2028	Date of Analysis: 16/03/2026
Manufactured for: American Remedies	Date of Release : 07/04/2026
STP No.: AP/02/FP/M002/00	

11.	Assay: (HPLC) Gastro resistant tablet contains:		
	Aspirin IP 75mg	(95.0%-105% of label claim of Aspirin)	74.28mg 99.04%
12.	Additional test* Microbial limit Test: Total bacterial count Total fungal count E coli Salmonella Staphylococcus aureus Pseudomonas aeruginosa	Not more than 1000 CFU/gm Not more than 100 CFU/gm Absent/gm Absent/10gm Absent/gm Absent/gm	30/cfu gm <10/cfu gm Absent Absent Absent Absent

Remarks: In the opinion of the undersigned, the sample referred to above is of Standard Quality/Not of Standard Quality as defined in the Drugs & Cosmetics Act 1940 & Rules made there under as per Specification No.: **AP/02/SPC/FP/M002/00**.

APPROVED

Prepared By		Checked By	Approved By
Name	<i>Kamalika</i>	<i>Ashwani Kumar</i>	<i>Raj Kiran</i>
Sign.	<i>[Signature]</i>	<i>[Signature]</i>	<i>[Signature]</i>
Date	07/04/2026	07/04/2026	07/04/2026